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The metabotropic glutamate receptor 7 (mGluR7) negative allosteric modulator, 6-(4-methoxyphenyl)-5-methyl-3-
pyridin-4-ylisoxazolo[4,5-c]pyridin-4(5H)-one (MMPIP), was locally microinjected into the ventrolateral periaqueductal
gray (VL PAG) and the effect on pain responses in formalin and spare nerve injury (SNI) -induced neuropathic pain
models was monitored in the rat. The activity of rostral ventromedial medulla (RVM) “pronociceptive” ON and
“antinociceptive” OFF cells was also evaluated. Intra–VL PAG MMPIP blocked the first and second phase of
nocifensive behaviour in the formalin pain model. MMPIP increased the tail flick latency and simultaneously
increased the activity of the OFF cells while inhibiting that of ON cells in rats with SNI of the sciatic nerve. MMPIP
failed to modify nociceptive responses and associated RVM ON and OFF cell activity in sham rats. An increase in
mGluR7 gene, protein and staining, the latter being associated with vesicular glutamate transporter-positive profiles,
has been found in the VL PAG in SNI rats. Blockade of mGluR7 within the VL PAG has an antinociceptive effect in
formalin and neuropathic pain models. VL PAG mGluR7 blockade offers a target for dis-inhibiting the VL PAG-RVM
pathway and silencing pain in inflammatory and neuropathic pain models.
Keywords: Metabotropic glutamate receptor subtype 7, Spare nerve injury, Ventrolateral periaqueductal grey,
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Metabotropic glutamate subtype receptor 7 (mGluR7) is
the most highly conserved [1] and widely distributed
among mGluRs, suggesting a critical role in regulating exci-
tatory synaptic transmission in the central nervous system
(CNS) [2-5]. It is mainly located in the active presynaptic
cleft of the glutamatergic synapse where it acts as auto-
receptor [6-10] or as hetereoreceptor controlling the release
of neurotransmitters other than glutamate [7,11]. The
characterization of the functional role of mGluR7 in the
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reproduction in any medium, provided the orlimited to mGluR7 knockout mouse studies until valuable
pharmacological tools for studying its function were
developed: the N,N’-dibenzyhydrylethane-1,2-diamine
(AMN082), a highly selective positive allosteric modu-
lator (PAM) [12] and the 6-(4-methoxyphenyl)-5-me-
thyl-3-(4-pyridin)-4ylisoxazolo[4,5-c]pyridin-4(5H)-one
(MMPIP) a negative allosteric modulator (NAM) which
exhibits intrinsic inverse agonist activity [13,14]. AMN
082 and MMPIP have been shown to penetrate the
blood–brain barrier in vivo [12,15].
Periaqueductal grey (PAG) is a key supraspinal site of
the antinociceptive descending pathway which includes
the rostral ventromedial medulla (RVM) and the dorsal
horn of the spinal cord. PAG control of pain is produced
concomitantly with the modulation of pain-responding
neurons of the RVM: the ON cells which are activated
and OFF cells which are inhibited by nociceptive stimuliLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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Figure 1 Time course of the nociceptive behaviour induced by
subcutaneous formalin (5% formalin, 50 μl, form) injected 10
min after the intra-VL PAG microinjection of vehicle (0.05%
DMSO in ACSF, 50 μl, Veh) or MMPIP (5 μg/0.2 μl). Recording of
nociceptive behaviour began immediately after the injection of
formalin (time 0) and was continued for 60 min. Each point
represents the total time spent lifting or licking the injected paw
(mean ± SEM). Time measurements were taken every 5 min. Each
group comprised 6–8 rats. * indicate significant differences vs rats
receiving intra-VL PAG ACSF and formalin into the dorsal surface of
the hind paw. P < 0.05 was considered statistically significant.
Palazzo et al. Molecular Pain 2013, 9:44 Page 2 of 12
http://www.molecularpain.com/content/9/1/44[16,17]. These cells also respond differently to centrally
acting analgesics: μ-opioid or CB1 receptor agonists depress
ON cell activity while they increase that of OFF cells
[16,18]. Neutral cells, another class of neurons found in the
RVM, are instead unaffected by noxious stimuli and anal-
gesic agents. mGluR7 stimulation by AMN082 has been
shown to facilitate pain behavior when microinjected into
the ventrolateral periaqueductal grey (VL PAG) [19] and in
the central nucleus of the amygdala (CEA) [20]. The pain
facilitatory effect due to mGluR7 stimulation in the VL
PAG was associated with consistent changes in the RVM
cell activity [19]. AMN082 also slightly reduced cold and
mechanical allodynia in neuropathic mice [21] when sys-
temically administered and inhibited cardiac nociception
when administered in the nucleus tractus solitarius (NTS)
[22]. Blockade of mGluR7 by systemic MMPIP has proven
not to change nociceptive thresholds in the tail immersion
test or in the first and second phase of the formalin test
[15]. Moreover, mGluR7 expression has been proven to de-
crease in the lumbar dorsal horn of mice with a neuro-
pathic pain condition [21], but has never been evaluated in
the PAG. Thus the role of mGluR7 in pain perception is
still far being established and in particular the effect of the
blockade of mGluR7 receptor at PAG level in healthy and
chronic pain conditions has never been investigated. In this
study we therefore microinjected MMPIP into the VL PAG
and evaluated the effect on: i) nocifensive responses in-
duced by a peripheral injection of formalin; ii) electro-
physiological changes in the RVM ON and OFF cell activity
and associated tail flick responses in a model of neuropathic
pain induced by the spared nerve injury (SNI) of the sciatic
nerve; iii) changes of mGluR7 expression in the VL PAG of
SNI rats.
Results
Effects of intra- VL PAG MMPIP on formalin-induced
nocifensive behavior
Formalin-induced nociceptive behavior was quantified by
calculating the amount of time that the rats spent lifting
and/or licking the formalin-injected hind paw. Control rats
receiving the subcutaneous injection of saline (0.9% NaCl)
into the hind paw did not display any nociceptive behavior
(n = 6, not shown). Subcutaneous injection of formalin in
rats receiving intra-VL PAG vehicle resulted in a typical bi-
phasic nociceptive response. The first phase was character-
ized by a first robust nociceptive response followed by a
transient decline thereafter. The second phase started 30
min after formalin reaching a peak at 50 min (Figure 1).
This nocifensive behaviour did not differ from that induced
by the peripheral injection of formalin alone. The intra-VL
PAG microinjections of MMPIP (5ug/0.2ul) significantly
reduced nocifensive responses in the first [F(2,14) =
179.66, P < 0.01, mixed design two-way ANOVA versus
rats receiving the intra-VL PAG microinjection of vehicleand the subcutaneous injection of formalin into the hind
paw] and second phase [F(2,14) = 120.77, P < 0.01), mixed
design two-way ANOVA versus rats receiving the intra-
VL PAG microinjection of vehicle and the subcutaneous
injection of formalin into the hind paw] of the formalin
test, as recorded 5 and 50 min after formalin peripheral
injection (Figure 1).Effect of intra-VL PAG microinjection of MMPIP on tail
flick latencies in sham and SNI rats
Tail flicks were elicited every 5 min for 15 min prior to
microinjecting MMPIP (5 μg/0.2 μl) or respective vehicle
into the VL PAG. Only rats whose microinjection site was
located within the VL PAG (black squares) were used for
data computation. Cannulae were also intentionally im-
planted 1 mm outside from VL PAG for control experi-
ments verifying the specificity of the area-induced effects
(white squares, n = 7) (Figure 2A). In SNI rats, latency to
the tail flick was significantly lower compared to that of
the shams [F(2,24) = 6.62, P < 0.05, mixed design two-way
ANOVA versus sham rats]. Intra-VL PAG microinjection
of vehicle did not change tail flick latency in sham and
SNI rats compared to pre-treatment values. Intra-VL PAG
microinjection of MMPIP (5 μg/0.2 μl) significantly in-
creased the tail flick latency compared to pretreatment
values in SNI rats (P < 0.05, n = 12, paired t test) (Figure 3B)
but was devoid of any activity in sham rats (Figure 3A).
MMPIP (5 μg/0.2 μl) was also intentionally microinjected
1 mm outside the VL PAG (n = 7), where it failed to
change tail flick latency (not shown).
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Figure 2 Representative schematic illustration of the microinjection sites for drug administration into the VL PAG (A) and electrode
positions within RVM (B). Coronal brain slices containing the VL PAG and recording sites into the RVM were processed after the experiment for
histological analysis. The numbers above the illustration show the distance from the bregma (Paxinos and Watson, 1998). Black squares indicate
microinjection site tips into the VL PAG and white squares those intentionally performed outside the PAG for placement controls (A). Circles
indicate electrode tips in the RVM, in particular white circles represent ON cells and black circles the OFF cells with overlapping tip positions
indicated with a single symbol (B). RMn, RGcn and RGcnα refer to nucleus raphe magnus, nucleus reticularis paragigantocellularis, nucleus
reticularis gigantocellularis pars α, respectively.
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ongoing activity of RVM ON and OFF in sham and SNI rats
In SNI rats, the population of OFF cells had a lower fre-
quency of spontaneous activity compared to that of the
shams [F(2,12) = 10.56, P < 0.001, mixed design two-way
ANOVA versus sham rats]. Microinjection of vehicle
(0.05% DMSO in ACSF) did not change the spontaneous
activity of the OFF cells compared to pretreatment values
in sham and SNI rats (Figure 3C and D). In sham rats, the
intra-VL PAG microinjection of MMPIP (5 μg/0.2 μl) did
not change the ongoing OFF cell activity (Figure 3C). In
SNI rats, intra VL-PAG microinjections of MMPIP (5 μg/
0.2 μl) caused a significant increase in the spontaneous fir-
ing activity of the OFF cells compared to pretreatment
values (P < 0.05, n = 6, paired t test) (Figure 3D). In sham
rats, the neurons identified as ON cells by a burst of activ-
ity just before tail flick responses were devoid of spontan-
eous activity in the majority of cases. In SNI rats, all
the ON cells encountered displayed spontaneous activity
and the intra-VL PAG microinjections of MMPIP (5 μg/
0.2 μl) caused a significant decrease in the spontaneousfiring compared to pretreatment values (P < 0.05, n = 6,
paired t test) (Figure 3E).
Effect of intra-VL PAG microinjection of MMPIP on tail
flick-related ON and OFF cell activity in sham and SNI rats
In SNI rats, the population of ON cells had a tail flick-
induced burst of firing frequency that was significantly
higher compared to the sham rats [F(2,12) = 8.80, P <
0.001, mixed design two-way ANOVA versus sham rats].
The onset of the burst was significantly lower in SNI rats
compared to the shams [F(2,12) = 644.1, P < 0.001, mixed
design two-way ANOVA versus sham rats]. The mean of
the frequency and the onset of the ON cell burst in the
sham rats did not differ from healthy rats. The population
of the OFF cells in SNI rats had a significantly longer pause
[F(2,12) = 19.9, P < 0.001, mixed design two-way ANOVA
versus sham rats] and a significantly shorter onset of pause
[F(2,12) = 348.04, P < 0.001, mixed design two-way ANOVA
versus sham rats]compared to the shams. The duration
and onset of the OFF cell pause in the sham rats did































































































Figure 3 Effects of intra-VL PAG microinjections of vehicle (0.05% DMSO in ACSF) or MMPIP (5 μg/0.2 μl) on tail flick latencies (A and B)
and the spontaneous firing of RVM OFF (C and D) and ON cells (E) in sham (A and C) and SNI (B, D and E) rats 14 days after surgery. Each
point represents the mean ± S.E.M of 12–14 (A and B) or 6–7 (C, D and E) rats per group. * indicates statistically significant difference vs pretreatment
values. P values < 0.05 were considered statistically significant.
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induced ON cell burst nor the onset of burst or the
OFF cell pause or the onset of the pause compared to
pretreatment values. Intra-VL PAG microinjection of
MMPIP (5 μg/0.2 μl) caused a decrease in both ON cell
burst (P < 0.05, n = 6, paired t test) and OFF cell pause
(P < 0.01, n = 5, paired t test) (Figure 4A and C) compared
to pre-treatment values in SNI rats. Intra VL-PAG micro-
injection of MMPIP (5 μg/0.2 μl) also caused an increase
in both the onset of ON cell burst (P < 0.01, n = 5, paired t
test) and the onset of OFF cell pause (P < 0.05; n = 5,
paired t test) (Figure 4B and D) compared to pre-
treatment values in SNI rats. The same treatment did
not change the tail flick-related activity of the ON or
OFF cell in sham rats. Representative ratemater records
showing tail flick-related activity of ON and OFF cells
in sham and SNI rats before and after MMPIP (5 μg/
0.2 μl) are shown in Figure 5.Gene expression of mGluR7
The semi-quantitative analysis of mRNA levels within
the VL PAG measured by RT-PCR amplification showed
a significant increase in the mGluR7 gene in SNI rats
(Figure 6A).
Western blotting
Western blot analysis showed a significant increase in
mGluR7 protein levels in the VL PAG in rats with SNI
(two-tailed unpaired Student’s t-tests, P < 0.01; t = −9.116,
n = 10) (Figure 6B).
Immunohistochemistry
Immunohistochemical analysis revealed a massive increase
of staining for mGluR7 in the VL PAG in rats with SNI
compared to sham operated rats, confirming the western
blotting measurement (Figure 6C). Moreover we found






















































































Figure 4 Effects of intra-VL PAG microinjections of vehicle (0.05% DMSO in ACSF) or MMPIP (5 μg/0.2 μl) on tail flick-evoked burst of
firing (A) and onset of the burst (B) of the ON cells or tail flick-evoked pause (C) and onset of the pause (D) of the OFF cells in sham
and SNI rats 14 days after surgery. Each histogram represents the mean ± S.E.M of 6–7 neurons of different treated groups of rats. * indicates
significant differences vs pretreatment values. P values < 0.05 were considered statistically significant.
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counterstained by mGluR7, assuming the autoreceptor na-
ture of the mGluR7. The predominant presynaptic nature
of mGluR7 has been corroborated by the double labelling
with synaptophysin, a presynaptic terminal marker.
Discussion
This study is the first to investigate the role of mGluR7
blockade in the VL PAG on formalin-induced pain be-
haviour, on tail flick latency and the activity of the RVM
ON and OFF cells in control and neuropathic pain con-
ditions in the rat. A subtype-selective negative allosteric
modulator for mGluR7 (MMPIP) [13,14] was microin-
jected into the VL PAG of rats receiving the injection of
formalin into the dorsal surface of the hind paw or rats
which had undergone the SNI of the sciatic nerve or sham
surgery. The key findings are as follows: intra-VL PAG
MMPIP inhibited the early and late phases of formalin-
induced nocifensive behavior; increased tail flick latency in
SNI rats and modified the ongoing and the tail flick evoked
activity of the ON and OFF cell of the RVM accordingly.
MMPIP was instead ineffective in sham animals.Our previous studies have shown that mGluR7 stimula-
tion plays a facilitatory role on pain. mGluR7 stimulation
by AMN082, a selective mGluR7 agonist [12], locally mi-
croinjected into the VL PAG and CeA, reduced the noci-
ceptive threshold [19,20,23]. AMN082 also decreased
extracellular glutamate release within the VL PAG [19].
Glutamate into the PAG relieves pain [24-26] thus due to
the autoreceptor role of mGluR7 [6,27-30], AMN082 may
lead to a decrease in glutamate level and subsequent pain
facilitation. We assume that the mGluR7 blockade by
MMPIP within the PAG would block this effect (the de-
crease in glutamate tone) thus dis-inhibiting the antino-
ciceptive descending pathway with consequent inhibition
of formalin-induced nocifensive behaviour. A recent study
has however shown that MMPIP had no analgesic effect in
either the tail immersion test or formalin test in mice when
systemically administered [15].
MMPIP has been shown to penetrate into the brain
after systemic administration [15] thus the effect of sys-
temically administered MMPIP involves brain, spinal and
peripheral mGluR7. The overall effect of systemic mGluR7


























































Figure 5 Examples of ratemater records which illustrate the effect of intra-VL PAG microinjection of MMPIP (5 μg/ 0.2μl) on either the
ongoing or tail flick-related burst of activity of identified RVM ON cells (A and B) and ongoing or tail flick-related pause of identified
RVM OFF cells (C and D) in sham and SNI rats. Intra-VL PAG microinjection of MMPIP (5 μg/0.2μl) did not change the ongoing activity and the
tail flick-related burst of the ON cell in sham rats (A) but reduced them in SNI rats (B). The same treatment did not modified the OFF cell activity
in the sham rats (C) but increased the ongoing activity and reduced the tail flick-related pause of the OFF cell in SNI rats (D). Scales bars indicate
5 min and small full arrows indicate the noxious stimulation application.
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mGluR7 localization on presynaptic elements of glutamate
or non –glutamate containing neurons [10,19,31,32]. The
combination of different/opposite effects could mask the
effect of MMPIP on nociceptive responses, determining
the lack of effect. A lack of effect of systemically adminis-
tered mGluR7 agonist, AMN082, has also been shown by
Stachowicz et al. [33] in the hot plate test whilst the intra-
thecal AMN082 administration has been shown to inhibit
both the early and late phase of formalin-induced pain be-
haviour [34].
Another concern of the following study is that the
blockade of mGluR7 by MMPIP within the VL PAG has
reduced the nocifensive behavior in both the first and sec-
ond phases of the formalin test. PAG stimulation has been
shown to inhibit the early and late phases of formalin-
induced nocifensive behavior [35]. By reducing the inhib-
ition of glutamate release through mGluR7 stimulation,
intra-VL PAG MMPIP would act as a PAG “indirect stimu-
lator” leading to pain inhibition [36-39]. Moreover, the sec-
ond phase of formalin test is the result of central neuronchanges produced by the neural activity generated during
the early phase [40-44], therefore the blockade of the early
phase prevents the development of the late phase.
The PAG modulatory effect on pain involves RVM which
lies downstream of the PAG and upstream of the dorsal
horn spinal cord. Within the RVM, ON cells, which show
a burst immediately prior to a nociceptive reflex [14,45,46],
have a facilitatory effect, whereas OFF cells, which show a
pause prior to a nociceptive reflex, have an inhibitory effect
on nociception [16,18,47]. The effect of intra-VL PAG mi-
croinjections of MMPIP on the ON and OFF cell activity
of RVM has been investigated in sham and SNI rats.
SNI induced marked pronociceptive changes in the
ongoing and tail flick-related activity of RVM ON and
OFF cells. The spontaneous discharge of the ON cells
was increased while that of the OFF cells decreased in
the SNI-operated rats. The ON cell burst and the OFF
cell pause were increased while the onset of the ON cell
burst and of the OFF cell pause proved to be decreased.
ON cell hyperactivity and OFF cell hypoactivity follow-
ing neuropathic pain in the pain descending system
A C
B
Figure 6 Expression of mGluR7 mRNA in the VL PAG: RT-PCR analysis starting from 100ng mRNA shows an increase for mGluR7 gene
expression in SNI rats compared to sham rats. Quantification of the expression levels is reported in the graphic that shows RT-PCR data value
for mGluR7 relative to the housekeeping 18S gene and normalized with respect to the mean of the shams (A). Western blot analysis for mGluR7
protein in PAG lysate from SNI and sham rats normalized with respect to β-tubulin and sham mean (B). Expression of mGluR7 in the PAG of SNI
and sham rats. Double staining shows the high expression of mGluR7 on vGluT positive terminals (right) and low expression on VGAT positive
terminals (left). Wave length is 568 nm for red staining and 488 for green staining (not shown) the merge was performed of 488 and 568
channels (yellow). Lowest panel indicate the double staining mGluR7 (red) synaptophysin (green) and relative merge (C). Purple spots indicate a
DAPI and red background/fluorescence spot overlapping. Scale bar = 100 μm. Data are represented as a mean ± SEM. p < 0.05 was considered
statistically significant.
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reported [48-53]. Intra-VL PAG MMPIP reverted SNI-
induced changes in both spontaneous and tail flick-related
activities of ON and OFF cells. In particular, it decreased
the burst frequency and increased the onset of the burst
of "pronociceptive" ON cells. Furthermore, MMPIP in-
creased the spontaneous activity of "antinociceptive" OFF
cells, reduced the pause duration and increased the onset
of the OFF cell pause in SNI rats.
These effects were consistent with a behavioural anti-
allodynic effect monitored simultaneously through tail flickin the SNI rats. An anti-allodynic rather then an anti-
nociceptive effect was suggested also by the fact that intra-
VL PAGMMPIP did not show any effect in the shams.
mGluR7 stimulation in the VL PAG instead induced op-
posite effects such as the facilitation of the ON cell activity
and the inhibition of OFF cell activity within the RVM
[19], consistently with behavioural pain facilitation [54].
mGluR7 is the most widely distributed presynaptic
mGluR subtype in the central and peripheral nervous
system [31,55]. Its xpression of mGluR7 proved to be
significantly down-regulated in dorsal root ganglia after
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after spinal nerve ligation [57]. Changes in expression of
mGluR7 in supraspinal areas such as the PAG in chronic
pain conditions are yet to be investigated. Upregulation
in the expression of mGluR7 gene and protein has been
observed in the VL PAG 14 days after neuropathic pain
induction. Therefore changes in expression of mGluR7
seem to be site specific and may justify the effect of
MMPIP in SNI rats and the lack of any effect in the
shams. The immunohistochemistry showed an increased
expression of mGluR7 being co-expressed with vGluT1
positive profiles. These increased mGluR7 positive pro-
files on vGluT1 counterstaining after SNI, indicated that
mGluR7 is over-expressed in neuropathic pain conditions
on glutamatergic neurons within the VL PAG, confirming
that MMPIP would act by dis-inhibiting the VL PAG
antinociceptive control.
Conclusion
The blockade of mGluR7 by microinjection of MMPIP
into the VL PAG inhibits nocifensive responses to formalin
and reduces thermonociception and ON cell activity, while
enhancing OFF cell activity in SNI rats. Intra-VL PAG
MMPIP did not affect thermal threshold or RVM ON and
OFF cell activity in the shams. Furthermore, mGluR7
proved to be over-expressed on glutamatergic terminals 14
days after SNI. It would therefore appear that intra VL
PAG blockade of mGluR7 offers a suitable strategy for acti-
vating the antinociceptive pathway and inhibiting pain re-
sponses in inflammatory and neuropathic pain conditions.
Methods
Animals
Male Sprague–Dawley rats (Harlan, Italy) weighing 250–
280 g were housed three per cage under controlled illu-
mination (12 h light/12 h dark cycle; light on 06.00 h) and
standard environmental conditions (ambient temperature
20-22°C, humidity 55–60%) for at least 1 week before the
commencement of experiments. Rat chow and tap water
were available ad libitum. All surgery and experimental
procedures were done during the light cycle and were ap-
proved by the Animal Ethics Committee of The Second
University of Naples. Animal care was in compliance
with the IASP and European Community (E.C. L358/1
18/12/86) guidelines on the use and protection of ani-
mals in experimental research. All efforts were made to
reduce both animal numbers and suffering during the
experiments.
Neuropathic pain
The spared nerve injury model of neuropathic pain was
induced according to the method used by Decosterd and
Woolf [58]. Rats were anaesthetised with sodium pento-
barbital (50 mg/kg, i.p.). The sciatic nerve was exposedat the level of its trifurcation into sural, tibial and com-
mon peroneal nerves. The sural and common peroneal
nerves were ligated tightly then transected just distal to
the ligation, leaving the tibial nerve intact. Sham rats
were anaesthetised, the sciatic nerve was exposed at the
same level, but not ligated. Thirteen days after surgery
sham and SNI rats underwent the surgical preparation
for intra-VL PAG microinjection (see below paragraph)
and the day after (14th after SNI) tail flick tests coupled
with single unit extracellular recording experiments were
carried out. Sham and SNI animals were sacrificed for
immunohistochemistry, RT-PCR and western blot ana-
lysis at 14th after SNI or sham surgery.Surgical preparation for intra-VL PAG microinjection
For in vivo studies (formalin test and single unit electro-
physiological recordings associated to tail flick) rats were
implanted with a guide cannula to perform direct intra-
VL PAG administrations. Briefly rats were anaesthetised
with pentobarbital (50 mg/kg, i.p.) and a 26-gauge, 12
mm-long stainless steel guide cannula was stereotaxically
lowered until its tip was 1.5 mm above the VL PAG by ap-
plying coordinates from the atlas of Paxinos and Watson
[59] (A: -7.8 mm and L: 0.5 mm from bregma, V: 4.3 mm
below the dura) controlateral to peripheral formalin injec-
tion or the sciatic nerve injury. The cannula was anchored
with dental cement to a stainless steel screw in the skull.
We used a David Kopf stereotaxic apparatus (David Kopf
Instruments, Tujunga, CA, USA) with the animal posi-
tioned on a homeothermic temperature control blanket
(Harvard Apparatus Limited, Edenbridge, Kent).
Direct intra-VL PAG administration was conducted
with a stainless steel cannula connected by a polyethylene
tube to a SGE 1-μl syringe, inserted through the guide
cannula and extended 1.5 mm beyond the tip of the guide
cannula to reach the VL PAG (Figure 2A). A group of rats
were implanted intentionally 1 mm outside the VL PAG
serving as placement controls in order to verify the speci-
ficity of the effect of the microinjection site (Figure 2A).
Volumes of 200 nl drug solution, or vehicle, were injected
into the VL PAG over a period of 60 sec and the injection
cannula gently removed 2 min later.In vivo experiment organization
In vivo experiments have been carried out 24 hours after
the surgery for guide cannula implantation.
Formalin test has been carried out in awake rats while
in vivo single unit electrophysiological recording associated
to tail flick in sham and SNI rats has been performed on
anaesthetized animals. Sham and SNI rats were undergone
to cannula implantation at the 13th day after sham or SNI
surgery in order to perform single unit electrophysiological
recording associated to tail flick at the 14th day.
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Formalin-induced pain is a widely used test for persis-
tent pain [60]. Fifty microliters of formalin (5%) or saline
solution (0.9% NaCl) were injected subcutaneously into
the dorsal surface of the hind paws of awake rats using a
30-gauge needle. Nociceptive responses were divided
into two phases: an initial early short phase (0–7 min)
caused by a primary afferent discharge produced by the
stimulus, followed by a quiescent period and a second
prolonged phase (15–60 min) of tonic pain (late phase).
Each rat was placed in a plexiglass testing chamber to
acclimatize for 30 min. A mirror was placed at a 45° angle
under the cage to allow a full view of the hind paws. Rats
which were undergone to formalin test received vehicle,
0.05% dimethyl sulfoxide, DMSO, in artificial cerebro-
spinal fluid (ACSF, composition in mM: KCl 2.5; NaCl
125; MgCl2 1.18; CaCl2 1.26) or MMPIP (5 μg) into the
VL PAG 10 min before formalin. Immediately following
formalin injection, rats were observed for 60 min by ex-
perimenter blind to the treatment. Paw lifting – the
injected paw was lifted off the cage floor, paw licking –
the injected paw was licked or bitten, were considered as
pain behaviour. The time spent lifting or licking the in-
jected paw was recorded every 5 min during the 60 min
after the formalin injection. Data are expressed in min as
mean ± SEM of the amount of time spent lifting and lick-
ing the injected hind paw.
Single unit extracellular recordings associated to tail flick
Single unit extracellular recordings associated to tail flick
have been carried out in the RVM while microinjecting
MMPIP (5 μg/0.2 μl) or respective vehicle (0.05% DMSO
in ACSF, 0.2 μl) into the VL PAG in sham and SNI rats. In-
deed previous studies have shown the presence of output
neurons from VL PAG projecting to RVM neurons [61,62].
20–24 hrs after the guide cannula implantation, anaesthe-
sia was induced with pentobarbital (50 mg/kg, i.p.) and
maintained with a continuous infusion of propofol (5–10
mg/kg/h, i.v.). A thermal stimulus was elicited by a radiant
heat source of a tail flick unit (Ugo Basile, Varese, Italy), fo-
cused on the rat tail approximately 3–5 cm from the tip.
The intensity of the radiant heat source was adjusted to 50
mW (corresponding to 50 mJ per sec) at the beginning of
each experiment in order to elicit a constant tail flick la-
tency. Tail flicks were elicited every 5 min for at least 15
min prior to microinjecting the drug or its vehicle into the
VL PAG. A glass-insulated tungsten filament electrode (3–
5 MW) (FHC Frederick Haer & Co., ME, USA) was
lowered into the RVM using the following stereotaxic co-
ordinates: 2.8–3.3 mm caudal to lambda, 0.4–0.9 mm lat-
eral and 8.9–10.7 mm depth from the surface of the brain
[59] (Figure 2B). RVM noxious stimuli-responding neurons
were identified by the characteristic OFF cell pause and
ON cell burst of activity immediately prior to tail flickresponses [47]. The recorded signals were amplified and
displayed on both analogue and a digital storage oscillo-
scope to ensure that the unit under study was unambigu-
ously discriminated throughout the experiment. Signals
were sampled by a CED 1401 interface (Cambridge Elec-
tronic Design Ltd., UK) and analyzed by Spike2 window
software (CED, version 4) to create peristimulus rate histo-
grams on-line and to store and analyse digital records of
single-unit activity off line. The configuration, shape, and
height of the recorded action potentials were monitored
and recorded continuously using Spike2 software for on-
line and off-line analyses. Once an ON or OFF cell was
identified from its background activity, we optimised spike
size before all treatments. This study only included neu-
rons whose spike configuration remained constant and
could clearly be discriminated from the background activ-
ity throughout the entire experiment. By doing so, we were
able to determine the activity of only one neuron. In each
rat, the activity of only a single neuron was recorded be-
fore and after vehicle or drug administration. Ongoing and
tail flick-related activity of the OFF cells was recorded be-
fore and after the VL PAG microinjection of vehicle or
MMPIP in shams and SNI rats 14 days after the surgical
procedure for neuropathic pain induction. For each OFF
neuron the ongoing activity was obtained by averaging the
firing rate (spikes/sec) for 50 sec before the tail flick trials
(carried out every 5 min). The latency to the onset of the
pause (time between the onset of heat application and the
last action potential) and the duration of the tail flick-
related pause (the time elapsing between the pause onset
and the first action potential following tail flick) of the
OFF cells were also quantified. Moreover, the peak height
of the tail flick-related burst (spikes/sec) and the onset of
the ON cell burst (the time elapsing between the onset of
heat application and the increase in the frequency rate,
which was at least twofold higher than its baseline) were
quantified for the ON cells. At the end of the experiment,
a volume of 200 nl of neutral red (0.1%) was injected into
the VL PAG 30 min before killing the rats with a lethal
dose of urethane. Rats were then perfused intracardially
with 20 ml phosphate buffer solution (PBS) followed by 20
ml of 10% formalin solution in PBS. The brains were re-
moved and immersed in a saturated formalin solution for
2 days. After fixation, the microinjection and recording
sites were identified (Figure 2B). The injection sites were
ascertained using two consecutive sections (40 μm), one
stained with cresyl violet to identify the VL PAG, and the
other unstained to determine dye spreading. The recording
site was marked with a 20 μA DC current applied for 20
sec immediately prior to the end of the electrophysio-
logical recordings. Only the data from microinjection and
drug diffusion sites located within the VL PAG and those
from the recording sites in RVM neurons were included in
the results. Groups of 10–12 rats per each treatment have
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and OFF cells with each animal being used for a single cell
recording.
Rats received 14 days after surgery a single intra VL
PAG microinjection of vehicle or MMPIP and were di-
vided as follows:
1) Sham and SNI rats receiving an intra-VL PAG
microinjection of vehicle,
2) Sham and SNI rats receiving intra-VL PAG
microinjection of MMPIP.
3) SNI rats (n = 7) receiving microinjection of MMPIP
intentionally 1 mm outside the VL PAG
mRNA extraction and reverse transcriptase-PCR
The VL PAG was homogenized and total RNA extracted
using an RNA Tri-Reagent (Molecular Research Center
Inc.) according to the manufacturer’s protocol. The ex-
tracted RNA was subjected to DNase I treatment at 37°C
for 30 min. The total RNA concentration was determined
using a UV spectrophotometer. The mRNA levels of the
gene for mGluR7 were measured by reverse transcript-
ase (RT)-PCR amplification. Sequences for rat mGluR7
mRNAs from GenBank (DNASTAR Inc.) were used to
design primer pairs for RT-PCRs (OLIGO 4.05 software,
National Biosciences Inc.). Each RT-PCR was repeated
at least four times by an experimenter who was blind to
the treatment. A semiquantitative analysis of mRNA
levels was performed by the Gel Doc 2000 UV System
(Bio-Rad). The measured mRNA levels were normalized
with respect to ribosomial subunit 18S, chosen as house-
keeping gene, and the gene expression values were ex-
pressed as mean of arbitrary units ± SEM.
Western blot
The VL PAG was first minced into small pieces with a
blender, and then suspended in lysis buffer (4% SDS, 20%
glycerol, 10% 2-mercaptoethanol, 0.004% bromophenol
blue, Tris–HCl, pH 6.8, containing 6 M urea, 50 μM
Na3VO4, 50 μM PMSF, Sigma) for protein extraction.
Total protein concentration was determined. Each sample
was loaded, electrophoresed in an 8% polyacrylamide gel,
and electroblotted onto a nitrocellulose membrane. To de-
tect mGluR7, a rabbit polyclonal primary antibody (Santa
Cruz Biotechnology, Inc) at 1:500 dilution was used. Fol-
lowing incubation, sections were washed and reincubated
with secondary antibody solution (donkey anti-goat, IgG-
HRP1:5000; Santa Cruz Biotechnology Inc). GE Healthcare
enhanced chemiluminescence (ECL) substrate (Pierce) was
used. Protein levels were normalized with respect to the
signal obtained with β-tubulin monoclonal antibodies
(Santa Cruz Biotechnology; 1:1000 dilution) chosen as
housekeeping protein, and the protein expression values
were expressed as mean of arbitrary units ± SEM.Immunohistochemistry
Sham and SNI rats were anaesthetized with pentobar-
bital (50 mg/kg, i.p.) and transcardially perfused with sa-
line solution followed by 4% paraformaldehyde in 0.1 M
phosphate buffer. The brain was removed, post fixed for
3 hours in the perfusion fixative, cryoprotected for 72
hours in 10, 20 and 30% sucrose in 0.1 M phosphate buffer
and frozen in O.C.T. embedding compound. Transverse
sections (15 μm) were cut using a cryostat and those
containing the whole PAG were thaw-mounted onto glass
slides. Sections were subsequently incubated for 1 day at
room temperature in a humid chamber with the respective
polyclonal antibodies (all diluted in specific block solution).
All sections were processed for goat anti-vesicular glu-
tamate transporter-1 (VGluT1) (1: 100, Santa Cruz,
USA), goat anti-vesicular GABA transporter (VGAT)
(1:100, SySy, Germany), rabbit-anti mGlu7 receptor (1:100,
Santa Cruz, USA) and anti-synaptophysin (rabbit poly-
clonal SySy, Germany). Following incubation, sections were
washed and incubated for 3 hours with secondary anti-
body solution (donkey anti-goat, or donkey anti-rabbit
IgG-conjugated Alexa FluorTM 488 and 568; 1:1000;
Molecular Probes, USA). Slides were washed, cover-slipped
with Vectashield mounting medium (Vector Laboratories,
USA) and visualized under a Leica fluorescence micro-
scope. Negative control by using secondary antibodies
alone did not reveal any positive staining. Toth and
Mezey [63] procedure has been used for the double
labelling.Drugs
6-(4-methoxyphenyl)-5-methyl-3-pyridin-4-ylisoxazolo[4,5-c]
pyridin-4(5H)-one (MMPIP) was purchased from Tocris
Bioscience (Bristol, UK) and was dissolved in 0.05% di-
methyl sulfoxide (DMSO) in ACSF (vehicle) on the day of
the experiment. The dose of MMPIP has been chosen
according to in vivo studies using intra-cerebral microin-
jections which have shown to antagonize AMN082 effects
[64,65].Data analysis and statistics
All data are given as means ± SEM. For behavioural and
electrophysiology experiments mixed design two-way
ANOVA has been used to analyze statistical differences
between the different groups of rats. Paired t test has
been used to compare post-injection versus pre-injection
values. Two-tailed unpaired Student’s t-tests was used
for biomolecular analysis and protein quantification. P
values < 0.05 were considered statistically significant.Competing interests
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